Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Scott M. Smith is active.

Publication


Featured researches published by Scott M. Smith.


Nature | 2005

Initial sequence of the chimpanzee genome and comparison with the human genome

Tarjei S. Mikkelsen; LaDeana W. Hillier; Evan E. Eichler; Michael C. Zody; David B. Jaffe; Shiaw-Pyng Yang; Wolfgang Enard; Ines Hellmann; Kerstin Lindblad-Toh; Tasha K. Altheide; Nicoletta Archidiacono; Peer Bork; Jonathan Butler; Jean L. Chang; Ze Cheng; Asif T. Chinwalla; Pieter J. de Jong; Kimberley D. Delehaunty; Catrina C. Fronick; Lucinda L. Fulton; Yoav Gilad; Gustavo Glusman; Sante Gnerre; Tina Graves; Toshiyuki Hayakawa; Karen E. Hayden; Xiaoqiu Huang; Hongkai Ji; W. James Kent; Mary Claire King

Here we present a draft genome sequence of the common chimpanzee (Pan troglodytes). Through comparison with the human genome, we have generated a largely complete catalogue of the genetic differences that have accumulated since the human and chimpanzee species diverged from our common ancestor, constituting approximately thirty-five million single-nucleotide changes, five million insertion/deletion events, and various chromosomal rearrangements. We use this catalogue to explore the magnitude and regional variation of mutational forces shaping these two genomes, and the strength of positive and negative selection acting on their genes. In particular, we find that the patterns of evolution in human and chimpanzee protein-coding genes are highly correlated and dominated by the fixation of neutral and slightly deleterious alleles. We also use the chimpanzee genome as an outgroup to investigate human population genetics and identify signatures of selective sweeps in recent human evolution.Here we present a draft genome sequence of the common chimpanzee (Pan troglodytes). Through comparison with the human genome, we have generated a largely complete catalogue of the genetic differences that have accumulated since the human and chimpanzee species diverged from our common ancestor, constituting approximately thirty-five million single-nucleotide changes, five million insertion/deletion events, and various chromosomal rearrangements. We use this catalogue to explore the magnitude and regional variation of mutational forces shaping these two genomes, and the strength of positive and negative selection acting on their genes. In particular, we find that the patterns of evolution in human and chimpanzee protein-coding genes are highly correlated and dominated by the fixation of neutral and slightly deleterious alleles. We also use the chimpanzee genome as an outgroup to investigate human population genetics and identify signatures of selective sweeps in recent human evolution.


The New England Journal of Medicine | 2009

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

Elaine R. Mardis; Li Ding; David J. Dooling; David E. Larson; Michael D. McLellan; Ken Chen; Daniel C. Koboldt; Robert S. Fulton; Kim D. Delehaunty; Sean McGrath; Lucinda A. Fulton; Devin P. Locke; Vincent Magrini; Rachel Abbott; Tammi L. Vickery; Jerry S. Reed; Jody S. Robinson; Todd Wylie; Scott M. Smith; Lynn K. Carmichael; James M. Eldred; Christopher C. Harris; Jason Walker; Joshua B. Peck; Feiyu Du; Adam F. Dukes; Gabriel E. Sanderson; Anthony M. Brummett; Eric Clark; Joshua F. McMichael

BACKGROUNDnThe full complement of DNA mutations that are responsible for the pathogenesis of acute myeloid leukemia (AML) is not yet known.nnnMETHODSnWe used massively parallel DNA sequencing to obtain a very high level of coverage (approximately 98%) of a primary, cytogenetically normal, de novo genome for AML with minimal maturation (AML-M1) and a matched normal skin genome.nnnRESULTSnWe identified 12 acquired (somatic) mutations within the coding sequences of genes and 52 somatic point mutations in conserved or regulatory portions of the genome. All mutations appeared to be heterozygous and present in nearly all cells in the tumor sample. Four of the 64 mutations occurred in at least 1 additional AML sample in 188 samples that were tested. Mutations in NRAS and NPM1 had been identified previously in patients with AML, but two other mutations had not been identified. One of these mutations, in the IDH1 gene, was present in 15 of 187 additional AML genomes tested and was strongly associated with normal cytogenetic status; it was present in 13 of 80 cytogenetically normal samples (16%). The other was a nongenic mutation in a genomic region with regulatory potential and conservation in higher mammals; we detected it in one additional AML tumor. The AML genome that we sequenced contains approximately 750 point mutations, of which only a small fraction are likely to be relevant to pathogenesis.nnnCONCLUSIONSnBy comparing the sequences of tumor and skin genomes of a patient with AML-M1, we have identified recurring mutations that may be relevant for pathogenesis.


Nature | 2008

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

Timothy J. Ley; Elaine R. Mardis; Li Ding; Bob Fulton; Michael D. McLellan; Ken Chen; David J. Dooling; Brian H. Dunford-Shore; Sean McGrath; Matthew Hickenbotham; Lisa Cook; Rachel Abbott; David E. Larson; Dan Koboldt; Craig S. Pohl; Scott M. Smith; Amy Hawkins; Scott Abbott; Devin P. Locke; LaDeana W. Hillier; Tracie L. Miner; Lucinda Fulton; Vincent Magrini; Todd Wylie; Jarret Glasscock; Joshua J. Conyers; Nathan Sander; Xiaoqi Shi; John R. Osborne; Patrick Minx

Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about 13,000 adults in the United States each year. The treatment of this disease has changed little in the past two decades, because most of the genetic events that initiate the disease remain undiscovered. Whole-genome sequencing is now possible at a reasonable cost and timeframe to use this approach for the unbiased discovery of tumour-specific somatic mutations that alter the protein-coding genes. Here we present the results obtained from sequencing a typical acute myeloid leukaemia genome, and its matched normal counterpart obtained from the same patient’s skin. We discovered ten genes with acquired mutations; two were previously described mutations that are thought to contribute to tumour progression, and eight were new mutations present in virtually all tumour cells at presentation and relapse, the function of which is not yet known. Our study establishes whole-genome sequencing as an unbiased method for discovering cancer-initiating mutations in previously unidentified genes that may respond to targeted therapies.


Nature | 2010

Genome remodelling in a basal-like breast cancer metastasis and xenograft.

Li Ding; Matthew J. Ellis; Shunqiang Li; David E. Larson; Ken Chen; John W. Wallis; Christopher C. Harris; Michael D. McLellan; Robert S. Fulton; Lucinda Fulton; Rachel Abbott; Jeremy Hoog; David J. Dooling; Daniel C. Koboldt; Heather K. Schmidt; Joelle Kalicki; Qunyuan Zhang; Lei Chen; Ling Lin; Michael C. Wendl; Joshua F. McMichael; Vincent Magrini; Lisa Cook; Sean McGrath; Tammi L. Vickery; Elizabeth L. Appelbaum; Katherine DeSchryver; Sherri R. Davies; Therese Guintoli; Li Lin

Massively parallel DNA sequencing technologies provide an unprecedented ability to screen entire genomes for genetic changes associated with tumour progression. Here we describe the genomic analyses of four DNA samples from an African-American patient with basal-like breast cancer: peripheral blood, the primary tumour, a brain metastasis and a xenograft derived from the primary tumour. The metastasis contained two de novo mutations and a large deletion not present in the primary tumour, and was significantly enriched for 20 shared mutations. The xenograft retained all primary tumour mutations and displayed a mutation enrichment pattern that resembled the metastasis. Two overlapping large deletions, encompassing CTNNA1, were present in all three tumour samples. The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour.


Nature Methods | 2013

DGIdb: mining the druggable genome

Malachi Griffith; Obi L. Griffith; Adam Coffman; James V. Weible; Josh F McMichael; Nicholas C. Spies; James Koval; Indraniel Das; Matthew B. Callaway; James M. Eldred; Christopher A. Miller; Janakiraman Subramanian; Ramaswamy Govindan; Runjun D. Kumar; Ron Bose; Li Ding; Jason Walker; David E. Larson; David J. Dooling; Scott M. Smith; Timothy J. Ley; Elaine R. Mardis; Richard Wilson

The Drug-Gene Interaction database (DGIdb) mines existing resources that generate hypotheses about how mutated genes might be targeted therapeutically or prioritized for drug development. It provides an interface for searching lists of genes against a compendium of drug-gene interactions and potentially druggable genes. DGIdb can be accessed at http://dgidb.org/.


PLOS Computational Biology | 2015

Genome Modeling System: A Knowledge Management Platform for Genomics

Malachi Griffith; Obi L. Griffith; Scott M. Smith; Avinash Ramu; Matthew B. Callaway; Anthony M. Brummett; Michael J. Kiwala; Adam Coffman; Allison A. Regier; Benjamin J. Oberkfell; Gabriel E. Sanderson; Thomas P. Mooney; Nathaniel G. Nutter; Edward A. Belter; Feiyu Du; Robert T. L. Long; Travis E. Abbott; Ian T. Ferguson; David L. Morton; Mark M. Burnett; James V. Weible; Joshua B. Peck; Adam F. Dukes; Joshua F. McMichael; Justin T. Lolofie; Brian R. Derickson; Jasreet Hundal; Zachary L. Skidmore; Benjamin J. Ainscough; Nathan D. Dees

In this work, we present the Genome Modeling System (GMS), an analysis information management system capable of executing automated genome analysis pipelines at a massive scale. The GMS framework provides detailed tracking of samples and data coupled with reliable and repeatable analysis pipelines. The GMS also serves as a platform for bioinformatics development, allowing a large team to collaborate on data analysis, or an individual researcher to leverage the work of others effectively within its data management system. Rather than separating ad-hoc analysis from rigorous, reproducible pipelines, the GMS promotes systematic integration between the two. As a demonstration of the GMS, we performed an integrated analysis of whole genome, exome and transcriptome sequencing data from a breast cancer cell line (HCC1395) and matched lymphoblastoid line (HCC1395BL). These data are available for users to test the software, complete tutorials and develop novel GMS pipeline configurations. The GMS is available at https://github.com/genome/gms.


BMC Bioinformatics | 2007

Design and implementation of a generalized laboratory data model

Michael C. Wendl; Scott M. Smith; Craig S. Pohl; David J. Dooling; Asif T. Chinwalla; Kevin Crouse; Todd G. Hepler; Shin Leong; Lynn K. Carmichael; Mike Nhan; Benjamin J. Oberkfell; Elaine R. Mardis; LaDeana W. Hillier; Richard Wilson

BackgroundInvestigators in the biological sciences continue to exploit laboratory automation methods and have dramatically increased the rates at which they can generate data. In many environments, the methods themselves also evolve in a rapid and fluid manner. These observations point to the importance of robust information management systems in the modern laboratory. Designing and implementing such systems is non-trivial and it appears that in many cases a database project ultimately proves unserviceable.ResultsWe describe a general modeling framework for laboratory data and its implementation as an information management system. The model utilizes several abstraction techniques, focusing especially on the concepts of inheritance and meta-data. Traditional approaches commingle event-oriented data with regular entity data in ad hoc ways. Instead, we define distinct regular entity and event schemas, but fully integrate these via a standardized interface. The design allows straightforward definition of a processing pipeline as a sequence of events, obviating the need for separate workflow management systems. A layer above the event-oriented schema integrates events into a workflow by defining processing directives, which act as automated project managers of items in the system. Directives can be added or modified in an almost trivial fashion, i.e., without the need for schema modification or re-certification of applications. Association between regular entities and events is managed via simple many-to-many relationships. We describe the programming interface, as well as techniques for handling input/output, process control, and state transitions.ConclusionThe implementation described here has served as the Washington University Genome Sequencing Centers primary information system for several years. It handles all transactions underlying a throughput rate of about 9 million sequencing reactions of various kinds per month and has handily weathered a number of major pipeline reconfigurations. The basic data model can be readily adapted to other high-volume processing environments.


Experimental Hematology | 2016

Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia

Malachi Griffith; Obi L. Griffith; Kilannin Krysiak; Zachary L. Skidmore; Matthew J. Christopher; Jeffery M. Klco; Avinash Ramu; Tamara Lamprecht; Alex H. Wagner; Katie M. Campbell; Robert Lesurf; Jasreet Hundal; Jin Zhang; Nicholas C. Spies; Benjamin J. Ainscough; David E. Larson; Sharon Heath; Catrina C. Fronick; Shelly O'Laughlin; Robert S. Fulton; Vincent Magrini; Sean McGrath; Scott M. Smith; Christopher A. Miller; Christopher A. Maher; Jacqueline E. Payton; Jason Walker; James M. Eldred; Matthew J. Walter; Daniel C. Link

The genomic events responsible for the pathogenesis of relapsed adult B-lymphoblastic leukemia (B-ALL) are not yet clear. We performed integrative analysis of whole-genome, whole-exome, custom capture, whole-transcriptome (RNA-seq), and locus-specific genomic assays across nine time points from a patient with primary de novo B-ALL. Comprehensive genome and transcriptome characterization revealed a dramatic tumor evolution during progression, yielding a tumor with complex clonal architecture at second relapse. We observed and validated point mutations in EP300 and NF1, a highly expressed EP300-ZNF384 gene fusion, a microdeletion in IKZF1, a focal deletion affecting SETD2, and large deletions affecting RB1, PAX5, NF1, and ETV6. Although the genome analysis revealed events of potential biological relevance, no clinically actionable treatment options were evident at the time of the second relapse. However, transcriptome analysis identified aberrant overexpression of the targetable protein kinase encoded by the FLT3 gene. Although the patient had refractory disease after salvage therapy for the second relapse, treatment with the FLT3 inhibitor sunitinib rapidly induced a near complete molecular response, permitting the patient to proceed to a matched-unrelated donor stem cell transplantation. The patient remains in complete remission more than 4xa0years later. Analysis of this patients relapse genome revealed an unexpected, actionable therapeutic target that led to a specific therapy associated with a rapid clinical response. For some patients with relapsed or refractory cancers, this approach may indicate a novel therapeutic intervention that could alter outcome.


Family Practice | 2004

The North Dublin randomized controlled trial of structured diabetes shared care

Scott M. Smith; Gerard Bury; Michael P. O'Leary; William Shannon; Tynan A; Staines A; Christopher J. Thompson


Nature | 2008

Genome analysis of the platypus reveals unique signatures of evolution (Nature (2008) 453, (175-183))

Wes Warren; Hillier Ldw.; J. A. Marshall Graves; Ewan Birney; Chris P. Ponting; Frank Grützner; Katherine Belov; Webb Miller; Laura Clarke; Asif T. Chinwalla; Shiaw-Pyng Yang; Andreas Heger; Devin P. Locke; Pat Miethke; Paul D. Waters; Frédéric Veyrunes; Lucinda A. Fulton; Bob Fulton; Tina Graves; John W. Wallis; Xose S. Puente; Carlos López-Otín; G R Ordó̃ez; Evan E. Eichler; Lin Chen; Ze Cheng; Janine E. Deakin; Amber E. Alsop; Katherine Thompson; Patrick J Kirby

Collaboration


Dive into the Scott M. Smith's collaboration.

Top Co-Authors

Avatar

David E. Larson

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

David J. Dooling

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Elaine R. Mardis

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Li Ding

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Sean McGrath

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Vincent Magrini

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Asif T. Chinwalla

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Devin P. Locke

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

James M. Eldred

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Jason Walker

Washington University in St. Louis

View shared research outputs
Researchain Logo
Decentralizing Knowledge